Bristol-Myers Squibb Shares Rise 2.12% Despite 58% Volume Drop to 151st Rank as Oncology Sales Outpace Partnership Charges

On August 1, Bristol-Myers Squibb (BMY) recorded a trading volume of $0.82 billion, a 58.09% decline from the previous day, ranking it 151st among stocks. The stock closed at $44.34, reflecting a 2.12% increase. Recent developments highlight mixed performance: the company’s Q2 2025 results showed strong growth in its oncology and hematology portfolios, including record sales for Breyanzi and Reblozyl, while a $0.57-per-share charge from its BioNTech partnership pressured earnings guidance. Regulatory approvals for OPDIVO in lung cancer and strategic collaborations further bolstered investor confidence.

Analysts remain cautiously optimistic despite macroeconomic headwinds. The company raised full-year revenue guidance to $46.5–$47.5 billion, driven by robust demand for key therapies. However, legacy portfolio declines and competitive pressures in markets like myosin inhibitors pose challenges. President Trump’s push for lower drug prices through most-favored-nation pricing adds regulatory uncertainty, though BMY’s high-volume growth assets suggest resilience in navigating industry dynamics.

A backtest of a strategy buying the top 500 stocks by daily trading volume and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This underscores the impact of liquidity concentration in short-term performance, particularly in volatile markets where high-volume stocks like BMY may see amplified movements due to institutional activity and market sentiment shifts.